((自动化翻译由路透提供，请见免责声明 ))
12月9日 - ** 药物开发商 BioAge Labs 股价盘前下跌 ~70% 至 6.13 美元
** 券商Jefferies将其股票评级从 "买入 "下调至 "持有"；将PT从42美元下调至7美元
** 与上周五收盘价 20.09 美元相比，新 PT 值下跌了 65.2
** 由于肝脏安全问题，该公司停止了中期肥胖症药物试验 (link)，因此券商下调了该公司的目标价。
** 券商预计 "股价将大幅下跌"
** 券商还将该公司的药物管线价值从 3 亿美元下调至 2 亿美元。
** 截至上次收盘，该公司股价已累计下跌 10.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.